Darnitsa presented the innovative Eridez® in the form of dispersible tablets25 May 2021
The pharmaceutical company Darnitsa presented the third generation antihistamine Eridez® in the form of tablets that are dispersible in the oral cavity.
Eridez® is used primarily to relieve the symptoms associated with allergic rhinitis, which affects 30% of the world's population*.
The active ingredient Eridez® desloratadine eliminates such symptoms of allergic rhinitis as sneezing, runny nose and itching, as well as eye irritation, tearing and redness, and itchy palate. Studies have shown that desloratadine has an antihistamine, anti-allergic effect. It helps ease nasal congestion due to a powerful anti-inflammatory effect, which begins after 30 minutes and persists throughout the day.
The oral disintegrating tablet or orally dissolving tablet (ODT) dosage form has a number of benefits for patients. It provides increased bioavailability, because the beginning of absorption of the drug occurs in the oral cavity. For the same reason, dispersible tablets are the optimal solution for patients with complications such as nausea, vomiting, seasickness. Also, this form is convenient for use when traveling and in situations with no access to water, for the use and maintenance of medical compliance in disabled or confined to bed patients.
Eridez® is recommended for adults and adolescents over 12 years of age, 1 tablet once a day, regardless of food intake.
Available without a prescription.